Massimo Guidoboni

15.3k total citations
86 papers, 3.3k citations indexed

About

Massimo Guidoboni is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Massimo Guidoboni has authored 86 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 33 papers in Immunology and 29 papers in Molecular Biology. Recurrent topics in Massimo Guidoboni's work include Cancer Immunotherapy and Biomarkers (29 papers), Immunotherapy and Immune Responses (26 papers) and CAR-T cell therapy research (18 papers). Massimo Guidoboni is often cited by papers focused on Cancer Immunotherapy and Biomarkers (29 papers), Immunotherapy and Immune Responses (26 papers) and CAR-T cell therapy research (18 papers). Massimo Guidoboni collaborates with scholars based in Italy, France and United States. Massimo Guidoboni's co-authors include Riccardo Dolcetti, Claudio Doglioni, Mauro Boiocchi, Maurilio Ponzoni, Antonia Anna Lettini, Antonio Russo, Alessandra Viel, Andrés J.M. Ferreri, Ettore Macrì and Michele Maio and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Massimo Guidoboni

83 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Massimo Guidoboni Italy	24	2.2k	1.3k	943	701	446	86	3.3k
Sylvia Hartmann Germany	31	1.6k 0.7×	1.6k 1.3×	759 0.8×	744 1.1×	270 0.6×	148	3.0k
Joost J. Oudejans Netherlands	34	1.3k 0.6×	1.3k 1.0×	815 0.9×	717 1.0×	275 0.6×	68	3.0k
Claudio Agostinelli Italy	30	1.5k 0.7×	2.0k 1.6×	992 1.1×	624 0.9×	324 0.7×	151	3.3k
Elizabeth Hyjek United States	29	1.8k 0.8×	671 0.5×	799 0.8×	1.1k 1.5×	356 0.8×	68	3.6k
Eric D. Jacobsen United States	30	1.9k 0.9×	2.6k 2.1×	1.1k 1.2×	792 1.1×	251 0.6×	145	4.5k
Javier Briones Spain	35	1.9k 0.8×	1.3k 1.1×	1.7k 1.8×	831 1.2×	254 0.6×	161	4.5k
Hans‐Dieter Foss Germany	32	1.7k 0.8×	2.4k 1.9×	1.1k 1.2×	774 1.1×	344 0.8×	69	4.0k
Harald Stein Germany	33	1.5k 0.7×	1.9k 1.5×	1.1k 1.2×	941 1.3×	224 0.5×	53	4.0k
Yoshitoyo Kagami Japan	35	1.9k 0.9×	2.3k 1.8×	1.0k 1.1×	739 1.1×	201 0.5×	102	3.9k
Marie‐Hélène Delfau‐Larue France	39	1.8k 0.8×	2.7k 2.2×	1.5k 1.6×	474 0.7×	358 0.8×	118	4.3k

Countries citing papers authored by Massimo Guidoboni

Since Specialization

Citations

This map shows the geographic impact of Massimo Guidoboni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Guidoboni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Guidoboni more than expected).

Fields of papers citing papers by Massimo Guidoboni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Guidoboni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Guidoboni. The network helps show where Massimo Guidoboni may publish in the future.

Co-authorship network of co-authors of Massimo Guidoboni

This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Guidoboni. A scholar is included among the top collaborators of Massimo Guidoboni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Guidoboni. Massimo Guidoboni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guidoboni, Massimo, et al.. (2026). Penile and scrotal eczema associated with enfortumab vedotin. Italian Journal of Dermatology and Venereology. 161(2). 177–179.

Magri, Chiara, Aldo Carnevale, Antonella Ciancetta, et al.. (2024). Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report. International Journal of Molecular Sciences. 25(14). 7508–7508.

Ascierto, Paolo A., Pietro Quaglino, Francesco Spagnolo, et al.. (2024). Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA9513–LBA9513. 2 indexed citations

Urso, Luca, Corrado Cittanti, E. Mastella, et al.. (2024). ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer. Diagnostics. 14(12). 1264–1264. 3 indexed citations

Willemsen, Marcella, Jenny Bulgarelli, Sudhir Kumar Chauhan, et al.. (2024). Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy. Immuno-Oncology Technology. 24. 101009–101009. 4 indexed citations

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654. 2 indexed citations

Granato, Anna Maria, Emanuela Scarpi, Laura Ridolfi, et al.. (2022). Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center. Vaccines. 10(7). 999–999. 5 indexed citations

Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745. 41 indexed citations

Aglietta, Massimo, Vanna Chiarion‐Sileni, Paolo Fava, et al.. (2021). Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology. 16(6). 789–799. 5 indexed citations

10.

Ascierto, P.A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2021). LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study. Annals of Oncology. 32. S1316–S1317. 18 indexed citations

11.

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2020). 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. Annals of Oncology. 31. S734–S734. 3 indexed citations

12.

Ascierto, Paolo A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2020). LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). Annals of Oncology. 31. S1173–S1174. 19 indexed citations

13.

Sznol, Mario, Pier Francesco Ferrucci, David Hogg, et al.. (2016). Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL). Annals of Oncology. 27. vi385–vi385. 2 indexed citations

14.

Martorelli, Debora, Massimo Guidoboni, Vallì De Re, et al.. (2012). IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas. Clinical Cancer Research. 18(15). 4080–4091. 11 indexed citations

15.

Farolfi, Alberto, Laura Ridolfi, Massimo Guidoboni, et al.. (2011). Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. Journal of Chemotherapy. 23(5). 300–305. 14 indexed citations

16.

Ridolfi, Laura, Massimiliano Petrini, Laura Fiammenghi, et al.. (2011). Dendritic cell-based vaccine in advanced melanoma. Melanoma Research. 21(6). 524–529. 27 indexed citations

17.

Pasini, Elisa, Laura Caggiari, Luigino Dal Maso, et al.. (2009). Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. International Journal of Cancer. 125(6). 1358–1364. 15 indexed citations

18.

Caselli, Elisabetta, Monica Galvan, Susana Álvarez, et al.. (2008). Retinoic acid analogues inhibit human herpesvirus 8 replication. SPIRE - Sciences Po Institutional REpository. 2 indexed citations

19.

Pratesi, Chiara, Maria Teresa Bortolin, Ettore Bidoli, et al.. (2005). Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunology Immunotherapy. 55(1). 23–30. 61 indexed citations

20.

Grazi, Enrico, Giorgio Trombetta, & Massimo Guidoboni. (1990). Microfilament gel rigidity cooperates negatively with the binding of actin gelling proteins.. PubMed. 21(4). 633–40. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact